

Nanomedicine and formulation for ddi solutions.

Carlos Sánchez Gómez*

Faculty of Chemistry, National Autonomous University of Mexico (UNAM), Mexico

Introduction

Nanomedicine presents a promising frontier for strategically addressing and effectively overcoming the multifaceted challenges posed by problematic drug-drug interactions (DDIs). This innovative field emphasizes the development of nanoparticle-based systems designed to significantly reduce the severity of DDIs. These advanced systems achieve this by precisely altering drug pharmacokinetics, substantially improving drug targeting capabilities, and enabling a more controlled and sustained release of therapeutic agents. The ultimate goal is to enhance therapeutic outcomes for patients and ensure a higher level of safety in their treatment regimens[1].

Pharmaceutical formulation plays an undeniably crucial role in achieving and significantly improving drug stability over extended periods. Recent advancements in formulation development, encompassing both novel delivery systems and sophisticated excipient strategies, are specifically engineered to protect active pharmaceutical ingredients (APIs) from various degradation pathways that are often driven by chemical reactivity, thereby ensuring the maintained efficacy and integrity of the drug product throughout its shelf life[2].

The inherent complexities associated with pharmacokinetic drug-drug interactions, meticulously detailing the various intricate mechanisms involved. These mechanisms include, but are not limited to, enzyme induction or inhibition and the critical modulation of transporter proteins. A deep understanding of these specific interactions proves absolutely critical for clinical practice, as it empowers clinicians to accurately predict and proactively manage potential adverse effects, or effectively address instances of altered drug efficacy, ultimately safeguarding patient well-being[3].

Nanoscale formulations can effectively overcome inherent biological barriers within the body. Their design allows them to deliver therapeutic agents specifically to disease sites while maintaining optimal drug concentrations over extended periods, leading to significantly improved treatment efficacy and a substantial reduction in systemic toxicity, thereby enhancing patient safety and therapeutic benefit[4].

The chemical reactivity of pharmaceutical excipients represents a major and ongoing concern within drug development. This review thoroughly details how undesirable interactions between active pharmaceutical ingredients (APIs) and excipients can regrettably lead to significant drug degradation. Such degradation negatively impacts the drug's stability, compromises its potency, and raises serious safety concerns. Consequently, it strongly emphasizes the paramount need for exceptionally careful and informed excipient selection during the critical phase of formulation design, ensuring robust drug product quality[5].

The intriguing and often complex impact that nanomaterials can have on drug-drug interactions. It meticulously discusses how the unique physicochemical properties intrinsic to nanoparticles possess the ability to significantly modify the absorption, distribution, metabolism, and excretion (ADME) profiles of co-administered drugs. This modification can either beneficially mitigate or, conversely, unfortunately exacerbate existing DDIs. This profound understanding is absolutely vital for the safe and responsible development of new nanomedicine formulations, ensuring their clinical utility[6].

Effectively managing drug-drug interactions in patients who are concurrently on complex therapeutic regimens presents a considerable and ongoing challenge for healthcare providers. This article comprehensively reviews various innovative formulation approaches specifically designed to mitigate DDIs. These approaches include the strategic use of fixed-dose combinations, advanced controlled-release systems, and novel excipient strategies. The overarching aim is to simplify dosing schedules, substantially improve patient adherence to treatment, and concurrently reduce the occurrence of adverse events, leading to better patient outcomes[7].

An innovative approach to predicting highly personalized drug interactions by intelligently integrating comprehensive chemical reactivity data with cutting-edge pharmacogenomic insights. A thorough understanding of an individual's unique genetic makeup, coupled with a deep appreciation for the intrinsic chemical properties of various drugs, demonstrably helps to anticipate specific DDI risks with greater precision. This novel approach paves a clear path for the development of more precise, highly effective, and ultimately safer personalized medicine strategies, tailoring treatments to indi-

*Correspondence to: Carlos Sánchez Gómez, Faculty of Chemistry, National Autonomous University of Mexico (UNAM), Mexico. E-mail: carlos.sanchez@univ-cdmx.mx

Received: 04-Sep-2025, Manuscript No. AAPCCS-25-200; Editor assigned: 08-Sep-2025, Pre QC No. AAPCCS-25-200 (PQ); Reviewed: 26-Sep-2025, QC No. AAPCCS-25-200; Revised: 07-Oct-2025, Manuscript No. AAPCCS-25-200 (R); Published: 16-Oct-2025, DOI: 10.35841/aapccs-9.4.200

vidual patient needs[8].

Nanotechnology offers a truly strategic and versatile avenue for drug repurposing, particularly in those challenging contexts where existing drugs face significant limitations primarily due to problematic drug-drug interactions. By cleverly reformulating established drugs into advanced nanocarriers, this sophisticated approach can effectively alter their pharmacokinetic profiles, significantly reduce undesirable off-target effects, and crucially, potentially circumvent existing DDIs. This innovative method breathes new life into older medicines, extending their therapeutic utility and applicability in patient care[9].

Pharmaceutical formulation profoundly impacts a drug's biopharmaceutical performance and its inherent potential for drug-drug interactions. This review specifically discusses how astute formulation choices, especially for drugs categorized under different Biopharmaceutical Classification System (BCS) classes, can directly and significantly influence critical aspects like absorption and metabolism. This, in turn, directly affects a drug's susceptibility to DDIs and, consequently, its overall clinical outcomes, emphasizing the importance of informed formulation decisions[10].

Conclusion

Nanomedicine offers strategic solutions for overcoming problematic drug-drug interactions (DDIs), leveraging nanoparticle systems to modify pharmacokinetics, improve targeting, and achieve controlled release, which ultimately enhances therapeutic outcomes and patient safety. Pharmaceutical formulation is pivotal for drug stability, with ongoing advancements in delivery systems and excipient strategies protecting active pharmaceutical ingredients from degradation and ensuring sustained efficacy. Understanding the complexities of pharmacokinetic DDIs, which involve mechanisms like enzyme induction, inhibition, and transporter modulation, is crucial for clinical practice to effectively predict and manage adverse effects or altered drug efficacy. Nanomedicines are transforming drug delivery through precise targeting and controlled release, efficiently navigating biological barriers and maintaining therapeutic drug concentrations while minimizing toxicity. The chemical reactivity of pharmaceutical excipients poses a significant challenge, as interactions with active ingredients can compromise drug stability, potency, and safety, underscoring the importance of meticulous excipient selection in formulation design. Nanomaterials demonstrably influence DDIs by altering the absorption, distribution, metabolism, and excretion (ADME) of co-administered drugs, making their safe

development paramount. To address the challenges of managing DDIs in complex therapeutic regimens, various formulation strategies, including fixed-dose combinations and controlled-release systems, are being developed. Predicting personalized drug interactions is advanced by integrating chemical reactivity data with pharmacogenomic insights, leading to more precise and safer personalized medicine. Furthermore, nanotechnology enables drug repurposing by reformulating existing drugs into nanocarriers, thereby altering their pharmacokinetic profiles and potentially circumventing DDIs. Overall, pharmaceutical formulation significantly impacts a drug's biopharmaceutical performance and its propensity for DDIs, with specific formulation choices influencing drug absorption, metabolism, and clinical outcomes.

References

1. Mohammad AA, Manal AT, Reem NA. Nanomedicine strategies for overcoming drug-drug interactions. *Drug Discov Today*. 2024;29:103790.
2. Yingying L, Minmin L, Weihua L. Recent Advances in Pharmaceutical Formulation Development and Its Application in Drug Stability Enhancement. *Front Pharmacol*. 2022;13:864555.
3. Xiaoyan C, Jun C, Yue M. Recent Advances in Pharmacokinetic Drug-Drug Interactions: Mechanisms and Clinical Implications. *Front Pharmacol*. 2021;12:703348.
4. Sumita K, Sayantan M, Sabyasachi M. Nanomedicines for Targeted Drug Delivery and Controlled Release: A Review. *J Pharm Sci*. 2023;112:36-58.
5. Pooja AS, Sandhya BP, Darshana TV. Chemical reactivity of pharmaceutical excipients and its impact on drug stability: A comprehensive review. *Eur J Pharm Sci*. 2020;153:105459.
6. Jing Z, Mingyue C, Pengfei L. Impact of Nanomaterials on Drug-Drug Interactions: A Systematic Review. *Pharmaceutics*. 2021;13:846.
7. Sumeet SK, Swapnil DJ, Nitin BM. Formulation approaches to mitigate drug-drug interactions in complex therapeutic regimens. *J Drug Deliv Sci Technol*. 2023;84:104523.
8. Chenxi X, Jiao A, Hongxia S. Integrating chemical reactivity with pharmacogenomics for personalized drug interaction prediction. *Sci Rep*. 2022;12:12154.
9. Anup KG, Kankana G, Anindya SG. Nanotechnology-driven drug repurposing: A strategic approach to overcome drug-drug interactions. *J Nanopart Res*. 2021;23:139.
10. Sarah LH, David RJ, Peter JS. Impact of Pharmaceutical Formulation on Biopharmaceutical Performance and Drug-Drug Interactions: A Comprehensive Review. *AAPS PharmSciTech*. 2020;21:118.

Citation: Gómez CS. Nanomedicine and formulation for ddi solutions. *J Pharm Chem Chem Sci*. 2025;09(04):200.